Researchers found that sucralose, a key ingredient in Splenda, promotes gut inflammation in mice with Crohn's-like disease, but has no effect on healthy mice. The study suggests that individuals with pro-inflammatory predispositions may be more susceptible to exacerbation of symptoms.
Researchers at the University of Central Florida have discovered a link between Mycobacterium avium subspecies paratuberculosis (MAP) and rheumatoid arthritis. The bacteria, commonly found in milk and beef, can trigger autoimmune responses in genetically predisposed individuals.
Researchers have made breakthroughs in IBD treatment with the approval of a new antibiotic and the use of Janus kinase inhibitors. These advancements aim to improve outcomes for patients who currently lack effective treatment options.
Studies show that home infusions can decrease infusion burden for selected patients and are cost-effective. Telemedicine may also improve outcomes but increases healthcare utilization. Urgent care access and patient education also lead to improved clinical outcomes and satisfaction.
Research presented at the Crohn's & Colitis Congress provides guidance for physicians to enhance IBD patient care. Studies show that better management of anemia improves overall outcomes, while IBD patients need better understanding of CRC screening intervals.
Researchers at Weill Cornell Medicine have identified a type of white blood cell that regulates the gut fungal population and protects against harmful fungi. This discovery sheds light on the mechanisms leading to ASCA generation, suggesting patients with certain gene variants may benefit from antifungal therapy.
Researchers found a higher frequency of LRRK2 gene mutations in Ashkenazi Jewish patients with Crohn's disease, which also increases the risk of developing Parkinson's disease. The study's findings could lead to better understanding and treatment of both conditions.
Researchers identified a mechanism where ileal Crohn's disease is induced by bile acids when T cell adaptation does not occur properly. Bile acid sequestrants may be an effective treatment for patients with impaired MDR1 expression, suggesting a potential new avenue for therapy.
A comprehensive study found that inflammatory bowel disease has become a global disease with accelerating incidence in newly industrialized countries. The research highlights the need for prevention and preparedness measures as these countries struggle to manage this complex and costly disease.
Researchers at Penn Medicine found that wiping out bad bacteria and re-introducing 'good' bacteria can reconfigure the gut microbiota, potentially treating Crohn's disease. The study used human and mouse studies to show that a single enzyme can regulate bacterial nitrogen metabolism and lead to dysbiosis.
The VIB-KU Leuven team presents a novel approach to analyzing gut microbiota, enabling the calculation of bacterial loads in fecal samples. This allows for a more accurate understanding of the relationship between microbiome composition and health parameters.
Researchers found that 46% of patients experienced mucosal healing after 48 weeks in a tight control protocol compared to 30% in clinical management. The study demonstrated superior outcomes using biomarker monitoring and symptom assessment.
Research suggests that mouth bacteria can contribute to conditions like IBD, UC, and Crohn's disease by triggering severe inflammation in susceptible individuals. The study found that saliva samples from patients with these diseases contain Klebsiella bacteria, which can colonize the intestine and exacerbate symptoms.
Clinical evidence supports the use of mesenchymal stem cell transplantation to treat Crohn's disease-related fistulas, offering a safe and effective approach. The unique advantages of MSCs include ease of collection, low immunogenicity, and immunoregulatory activity.
A six-year study of nearly 1 million people found that autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel diseases increase cardiovascular risk and mortality. The study's results highlight the need for better tools to predict cardiovascular events in these populations.
Exclusion of solid food allows for effective control of Crohn's disease inflammation and promotes faster healing compared to steroid treatment. Liquid nutrition provides a viable option for managing the condition in pediatric patients.
Researchers at UT Southwestern Medical Center have discovered a link between the backup immune defense system and mutation seen in Crohn's disease. The study found that a backup pathway uses autophagy's cellular machinery to deliver protein weapons to the cell surface, making it more effective against bacterial attacks.
Researchers at Case Western Reserve University found that a high fat diet rich in plant-derived 'good' fats reduced bacterial diversity and inflammation in mice with Crohn's-like disease. This discovery could lead to new anti-inflammatory probiotics and provide hope for patients suffering from debilitating intestinal symptoms.
Researchers found that Candida tropicalis infection intensifies Crohn's disease symptoms in mice by modulating gut bacteria and triggering inflammation. The study suggests anti-fungal medications could be beneficial in combating debilitating symptoms of the disease.
Scientists identified a key gene, MDR1, governing toxin removal in the gut, which is linked to bowel disorders like Crohn's disease. Targeting vital cell parts with drugs can reverse damage and improve outcomes.
Recent clinical trials show biologics like infliximab and adalimumab promote 28-33% mucosal healing in Crohn's disease and ulcerative colitis. Researchers aim to develop new treatments targeting inflammation differently.
A study by Arizona State University and Mayo Clinic identified several unique biomarkers, called autoantibodies, that can accurately diagnose Crohn's disease. The discovery has the potential to provide early warning for those at risk of major illnesses, including cancer, autism, and diabetes.
A new study found that a strain of Saccharomyces cerevisiae can worsen intestinal damage in mouse models of colitis by causing elevated uric acid levels. Blocking this yeast strain may alleviate symptoms of inflammatory bowel disorders in some patients, according to the researchers.
A study published in Science Immunology reveals that a variant of the SP140 protein, an essential epigenetic reader protein, is lacking in patients with Crohn's disease. This deficiency triggers intestinal inflammation and impairs the immune system's response to microbial signals. The researchers found that patients with reduced SP140 ...
A new biosimilar called CT-P13 has been found safe and effective in treating Crohn's disease and ulcerative colitis, with a clinical response achieved in over 70% of patients at short-term follow-up. The treatment offers a cost-effective alternative to infliximab, a costly biologic therapy.
Grimes, assistant professor in UD's Department of Chemistry and Biochemistry, will use her fellowship to investigate how chronic inflammatory diseases, such as asthma and Crohn's disease, arise from bacterial cell wall fragments. Her work aims to understand the immune system's response to these molecules.
New research uncovers a connection between Crohn's disease and spondyloarthritis, finding that IgA-coated E. coli bacteria trigger inflammation in Th17 cells. This discovery may lead to the development of diagnostic tools and therapies targeting both conditions.
Pre-operative liquid feeding is associated with reduced post-operative abscesses and intestinal leakage by nine-fold, with only one of 38 patients developing these complications. This study suggests exclusive enteral nutrition as a bridge to safer semi-elective surgery for complicated Crohn's disease patients.
Researchers identified genetic variants that affect Crohn's disease severity, but found these variants do not determine individual risk of developing the condition. The study suggests new pathways for treating established disease.
Researchers developed a sensor that uses Raman spectroscopy to detect molecular markers of IBD in the colon, helping to distinguish between ulcerative colitis and Crohn's disease. The device could provide an objective gold standard for diagnosis and guide personalized treatment approaches.
Researchers at University of California San Diego School of Medicine found that ustekinumab induces response and remission in patients with Crohn's disease. The study showed high remission rates among patients treated with intravenous or subcutaneous ustekinumab.
Scientists have identified two distinct genetic subtypes in Crohn's disease patients, each with unique patterns of gene expression and clinical features. This discovery could lead to more effective treatment strategies tailored to individual patients' needs.
Researchers are exploring the connection between Johne's disease in cattle and Crohn's disease in humans. The study found that MAP-infected cows share symptoms with Crohn's patients, including thickened intestines, diarrhea, and low protein absorption.
Scientists at the University of British Columbia have made a groundbreaking discovery that could lead to treatments for fibrosis in Crohn's patients. Researchers found a mutation in mice that prevented fibrosis after infection, targeting a hormone receptor responsible for stimulating part of the immune response.
A UK-wide trial found that smokers with Crohn's disease are more likely to experience a recurrence after surgery. The study suggests that quitting smoking is crucial in preventing the condition from worsening.
Researchers at Case Western Reserve University aim to understand the role of intestinal innate immunity in Crohn's disease. They will investigate how mice develop experimental Crohn's disease and replicate these findings in humans, with the goal of developing new medications and treatments to cure the devastating ailment.
Researchers at Penn State College of Medicine developed a new care plan for managing septic perianal Crohn's disease, which combines medical and surgical treatments. The plan resulted in a 60% healing rate among patients, with half requiring permanent ostomy bags while the other half saw some improvement but did not heal completely.
Researchers discovered that genetic mutations in certain genes can impair the immune-enhancing effects of beneficial bacteria, leading to reduced efficacy of probiotic therapies in treating Crohn's disease. The study suggests a new potential cause for the disorder and may lead to advances in personalized medicine.
Researchers at Cedars-Sinai Medical Center discovered that genetic variants can prevent 'good' gut bacteria from functioning properly, contributing to the development of Crohn's disease. This study provides new insight into the interaction between genes and microorganisms in promoting health and preventing inflammation.
The specialty medical home approach aims to provide comprehensive, cost-effective care for patients with inflammatory bowel diseases. This model focuses on patient-centered care, social support, and mental health, addressing high rates of emotional difficulties and poor social support experienced by these patients.
A national research study will focus on the effectiveness of specific carbohydrate diets and Mediterranean-style diets to induce remission in patients with Crohn's disease. The study, led by Dr. James Lewis, aims to provide high-quality data and guidance for incorporating diet modifications into the treatment of the disease.
A new study by Hasbro Children's Hospital reveals Rhode Island has one of the highest rates of inflammatory bowel disease (IBD) in the US. The nationwide trend suggests a need for more research into IBD causes and targeted treatments.
Scientists designed a novel bispecific antibody that selectively blocks overproduction of TNF, a protein harmful when overproduced in autoimmune diseases. The prototype shows promise for treating conditions such as rheumatoid arthritis and Crohn's disease.
A study published in Gut journal found that oral and intravenous iron replacement therapies alter the gut microbiota significantly, particularly in Crohn's disease patients. These changes may lead to unstable bacterial ecosystems and increased risk of disease flares.
A clinical trial found that stem cell transplantation did not provide significant improvement in sustained disease remission after one year for patients with difficult-to-treat Crohn's disease. However, some patients showed objective signs of disease disappearance and discontinued active treatment more frequently in the stem cell group.
A study published in JAMA found that hematopoietic stem cell transplantation does not provide significant improvement for adults with difficult-to-treat Crohn's disease. The treatment was associated with increased toxicity, but no difference in sustained remission rates compared to conventional therapy.
A genetic study of 35,000 patients with inflammatory bowel disease (IBD) reveals new insights into disease progression and severity. The research suggests that IBD may be an array of bowel disorders, rather than a single condition, and could lead to more effective treatments if identified early.
A mindfulness-based group intervention significantly reduces anxiety, depression, and improves quality of life in patients with inflammatory bowel diseases. Six months later, the benefits persist, making mindfulness practices a feasible and effective treatment option.
A study of over 30,000 patients found that Crohn's disease and ulcerative colitis share similar genetic markers, suggesting a continuum of disorders. Genetic data can help identify misdiagnoses and inform treatment guidelines.
A study by researchers at the University of Pennsylvania School of Medicine found that different treatments for Crohn's disease in children have distinct effects on their gut microbiome. The use of antibiotics suppressed bacterial growth but facilitated fungal growth, while immunosuppressant medications reduced inflammation and bacteri...
A recent study found that diet-based and anti-inflammatory therapies alter different components of the microbial community without fully restoring the normal balance of gut bacteria and fungi in children with Crohn's disease. The treatment did not restore the normal balance of gut microbes, despite reducing inflammation.
A novel protein has been identified as a key player in preventing bowel inflammation, which is a major cause of Crohn's disease and ulcerative colitis. The discovery could lead to the development of targeted therapies for these conditions.
Researchers found that palmitic acid, a saturated fatty acid found in olive oil and meat, worsened inflammation in Crohn's disease. Omega-6 fatty acid, present in vegetable oils, actually reduced inflammation in the condition.
Dr. Theresa Alenghat receives $100,000 grant to study epigenetics role in IBD development and progression. Her research aims to test the hypothesis that dysregulation of epigenomic modifications and microbiota alterations drive IBD.
The study identified gene variants within three highly associated regions for Crohn's disease, including NOD2 and interleukin 23 receptor. Additionally, the researchers found novel regions of chromosomes 2 and 3 to be causative for IBD in African-Americans.
A recent study published in Cellular and Molecular Gastroenterology and Hepatology found that intra-abdominal fat cells may promote inflammation in IBD patients. The research isolated and cultured pre-intra-abdominal fat cells from healthy subjects and those with IBD, revealing significant differences in signaling mediators produced by...
The Crohn's & Colitis Foundation is establishing the world's largest database for Crohn's disease and ulcerative colitis research, which will integrate patient information, genetic profiles, and clinical data. The $17.5 million initiative aims to speed progress toward precision medicine and potential cures.
A study reveals that an unfavorable bacterial network configuration in the gut can cause inflammation similar to Crohn's disease. Researchers found that transplanting 'healthy' bacteria into patients' intestines may provide a conventional treatment option.
Women with inflammatory bowel disease (IBD) are at a higher risk of developing cervical dysplasia and cancer, according to a new study. Researchers found that patients with Crohn's disease had a significantly higher risk of cervical neoplasia, especially those diagnosed at a young age or treated with certain medications.
A recent study published in the IBD Journal found significant racial disparities in the treatment and outcomes of children with Crohn's disease. Black children had a 1.5 times higher frequency of hospital readmissions due to Crohn's disease compared to white children.